Circulating tumour cell isolation and enrichment for investigation of prostate cancer metastasis

Résumé fourni par la source

Introduction: Circulating tumour cell (CTC) burden is an established marker of poor prognosis and worse overall survival for patients with metastatic prostate cancer, offering insight into disease progression. Methods to enrich for CTCs often rely on immune-affinity techniques targeting EpCAM. Such methods may fail to capture CTCs that have downregulated EpCAM expression, for example as a result of epithelial-to-mesenchymal transition (EMT). Label-free methods of enrichment are able to capture CTCs in all stages of the EMT.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.